A total of 61 patients were screened for eligibility. The
characteristics of the included sample are reported in Table 1. The most common reasons for noneligibility were age and acute psychosis. All participants (N = 13) were prescribed concurrent psychiatric medications and n = 1 was treated with ECT parallel to BA. Of the 13 participants that started treatment n = 10 completed the minimum of 8 sessions. Ruxolitinib mouse A total of n = 9 completed 11 or 12 sessions. Three patients dropped out prematurely at Session 1 (n = 1) or 2 (n = 2). One participant stated that she dropped out due to significant memory loss following the ECT. The mean duration of BA-treatment for completers was 9.3 weeks (SD = 3.1). The mean number of sessions received during hospital admission was 3.5 (SD = 2.4). The mean duration of inpatient admission was 20.4 days (SD = 14.4). One participant was rehospitalized during the treatment period but was discharged prior to the last session. Results from the TCS after Session 3 (M = 40.5, SD = 6.2) indicated high credibility and expectancy for change. The CSQ-8 after treatment (M = 28.2, SD = 3.3)
indicated high satisfaction. Results from the WAI at Session 3 (M = 66.2, SD = 11.2), Session 6 (M = 70.6, SD = 7.3), and Session 9 (M = 75.40, SD = 7.1) Ferroptosis inhibitor review indicated a good working alliance. A one-way repeated measures ANOVA indicated that it improved over the Atorvastatin course of treatment, F(2, 18) = 4.912, p = .02. Following treatment participants were also asked open-ended questions about their experience of therapy. Below we report the answers that did not overlap each other: 1. What did you think about initiating
therapy while admitted on the inpatient unit? The BADS-SF total score improved gradually over the course of treatment from baseline (M = 16.20, SD = 6.4), Session 3 (M = 20.8, SD = 6.2), Session 6 (M = 25.4, SD = 6.1), Session 9 (M = 29.1, SD = 5.6) to posttreatment (M = 33.10, SD = 10.6). A one-way repeated measures ANOVA for BADS-SF indicated a significant time effect, F(4, 48) = 10.367, p < .001. Descriptive statistics for participants’ homework compliance are reported in Table 2. Significant improvements and large effect sizes were indicated for MADRS-S, F(4, 36) = 18.79, p < .001, d = 2.60), clinician rated MADRS, t(9) = 6.292, p < .001, d = 2.43, self reported GAF, t(9) = -4.525, p < .001, d = 2.11, and the clinician-rated GAF, t(9) = -5.628, p < .001, d = 2.21. No significant improvements were observed in the SDS, t(9) = 2.101, p = .065, d = .63. The above pattern of significance and effect size magnitude was repeated when looking at the intention-to-treat sample using last observation carried forward. Changes in BADS-SF from baseline to posttreatment were significantly correlated with depressive symptom improvements over the course of treatment on the MADRS-S (r = -.681, p = .01).